Inherited genetic information can inform oncology practice using protocols for patient ascertainment, testing, counseling, prevention, and treatment. For example, carriers of germline BRCA1/2 or Lynch Syndrome mutations are at increased risk of breast, ovarian, prostate, endometrial, colorectal, and other cancers. Genetic testing is of clinical value because many mutations are actionable in reducing risk or determining appropriate treatment regimens. There is growing evidence that inherited genetic mutations represent a large proportion of cancer cases in sub-Saharan Africa (SSA). However, genetic testing, counseling, and clinical management protocols have largely not been developed in SSA. In order to increase the capacity for cancer genetic testing and counseling in SSA, this course will provide a foundation for clinicians without specific training in clinical cancer genetics who wish to understand this field and incorporate this into their practice.